
News|Videos|December 6, 2020
The Development and Treatment Potential of FTX-6058
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what FTX-6058 is, how it was developed, and what it is able to treat.
Advertisement
Pharmacy Times® interviewed Christopher Moxham, the senior vice president of discovery research at Fulcrum Therapeutics, on his presentation at the 62nd ASH Annual Meeting and Exposition. The presentation discusses research into the induction of fetal hemoglobin by FTX6058, a novel small molecule development candidate.
In this video, Moxham explains what FTX-6058 is, how it was developed, and what it is able to treat.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan
2
Toothpaste Tablets Are Gaining Popularity—Here’s Where Pharmacists Fit In
3
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist Therapy
4
Twists, Turns, and Tapers: Navigating the Benzodiazepine Ride
5













































































































































































































